Short Summary
The Director reviewed multiple IPRs against Birchtech's patents, instructing the Board to consolidate parallel proceedings into a single petition per patent if RPI requirements are met.
Detailed Summary
This Order supplements a prior Director Review Decision concerning several Inter Partes Reviews (IPRs) challenging various patents. The review addressed issues of Real Party in Interest (RPI) and privity, specifically focusing on the permissibility of multiple petitions against the same patent. Citing a precedent set in PacifiCorp, the Director instructed the Board to maintain at most one IPR for each challenged patent if petitioners successfully demonstrate they have identified all RPIs.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Berkshire Hathaway Energy Company et al. vs MES, Inc. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Apple Inc.vsCardWare Inc.
The USPTO Director denied institution for multiple Inter Partes Review (IPR) proceedings, preventing trials in these cases.
Alpinestars S.p.A et al.vsDainese S.p.A.
Alpinestars and Dainese have executed a settlement that ends all pending cross‑border patent disputes over airbag technology for motorcyclists. The agreement includes dismissal of lawsuits, withdrawal of oppositions, and a mutual non‑challenge pledge.
NVIDIA CorporationvsLowenstein and Weatherwax LLP
NVIDIA has filed an IPR petition seeking to invalidate 48 claims of its reissued RE48,438 patent covering GPU‑based artificial neural‑network processing. The challenger relies on four prior‑art references—Kirk, Oh, Tamura, and GPU Gems—to argue obviousness under § 103. The Board has yet to decide whether to institute the review.
QIAGEN Sciences, LLCvsTecan Group AG
Tecan Group AG seeks Director Review to overturn a PTAB institution decision that granted QIAGEN's IPR petition challenging its genotyping patent. The owner contends the panel abused discretion, over‑relied on expert testimony, and ignored policy against multiple parallel petitions.
Imperative Care, Inc.vsInari Medical, Inc. et al.
The PTAB has instituted an inter partes review of Inari Medical’s hemostasis valve patent after finding Imperative Care’s petition shows a reasonable likelihood of success. The review will cover claims 1‑9 and is based on anticipation and obviousness grounds over Schaffer, Hartley, and Eller references.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.